Estudio demuestra que quitosana/IL-12 es una sustancia efectiva para inmunoterapia anti-tumores

A new study by a University of Arkansas biomedical engineer and his colleagues at the National Cancer Institute demonstrates further promise for chitosan/interleukin-12 as an effective anti-tumor immunotherapy. The researchers had already demonstrated success with chitosan/IL-12 in the treatment of superficial bladder cancer in mice, for which human clinical trials will likely begin in 2011. But recent findings revealed that injections of chitosan/IL-12 eradicated aggressive colorectal and pancreatic tumors as well.